Valuations of Early-Stage Companies and Disruptive Technologies
Springer International Publishing (Verlag)
978-3-030-38846-1 (ISBN)
Tiran Rothman has more than a decade of experience in financial consultancy and academic and applied research in behaviour finance and economics. As Head of Frost & Sullivan Israel, he leads the largest private financial valuation program for high-tech companies and the Tel Aviv Stock Exchange Equity Research Program, which covers pharmaceutical, biotechnology, medical device, ICT, Renewable Energy, Autonomous Vehicle and Cybersecurity companies. He previously served as Chief Economist of AMPAL (NASDAQ:AMPL). Tiran is also an assistant professor and Dean of the School of Management at the Wizo Academic Center Haifa. He holds a PhD in Behavioural Economics from the University of Haifa, an MBA (Finance) from IDC Herzliya and was a visiting fellow at Stern Business School, NYU. He has been published in the field of behavioural finance and has been the recipient of numerous research grants and scholarships. Daniel Grunstein spent two years as an equity research analyst at Frost & Sullivan covering pharmaceutical, biotechnology, medical device, ICT, Renewable Energy, and Cybersecurity companies. Since 2018, he has served as a Strategy and Research Analyst at JPMorgan's Israel Innovation & Technology Center focusing on financial technology and enterprise software. His true passion is autonomous vehicles as vectors of smart and sustainable urban economics. He is currently completing an MSc in Sustainable Urban Development at the University of Oxford with plans to continue to a PHD in 2020. His research focuses on autonomous vehicles and the effect of this transition on long-held assumptions of economic geography. Daniel holds a BA in International Relations and Economics from the University of Sydney and an MBA in Strategy and New Product Development from Tel Aviv University. He has a growing portfolio of academic publications, has been the recipient of numerous scholarships, and completed several fellowships.
Part I. A Short Overview of Valuations.- Chapter 1. Introduction.- Chapter 2. Understanding Financial Valuations and Basic Traditional Techniques.- Part II. Overcoming Valuation Hurdles: How to Conduct Valuations Under Unique Circumstances.- Chapter 3. Understanding the Basic Elements of Stockholder Statements and their Use in Valuations.- Chapter 4. Valuation Methods: The First Chicago Venture Method and the Use of Real Options.- Part III. Behavioral Factors: How Psychology Affects Bias in Valuations.- Chapter 5. Introduction to Behavioral Finance.- Chapter 6. An Overview of Investor Behavior in Financial Markets and Psychological Influences on Valuations.- Chapter 7. How to Overcome Investor Behavior and Psychological Influences in Valuations: How to Evaluate a Dream?.- Part IV. An Introduction to Valuations in R&D-Intensive Industries.- Chapter 8. The Pharmaceutical Sector.- Chapter 9. Life Sciences: Disrupting Biologic Drugs Manufacturing.- Chapter 10. An Overview of the Cybersecurity and the Renewable Energy Sectors.- Part V. Actual Valuations.- Chapter 11. Company A: Pharmaceutical / New Compounds.- Chapter 12. Company B: Pharmaceutical / Biologies.- Chapter 13. Company C: Cybersecurity.- Chapter 14. Company D: Renewable Energy.- Chapter 15. Conclusion.
Erscheinungsdatum | 29.12.2020 |
---|---|
Zusatzinfo | XII, 219 p. 11 illus., 5 illus. in color. |
Verlagsort | Cham |
Sprache | englisch |
Maße | 155 x 235 mm |
Gewicht | 472 g |
Themenwelt | Wirtschaft ► Betriebswirtschaft / Management ► Finanzierung |
Schlagworte | biotech projects • Corporate value • cybersecurity companies • Discounted Cash Flow • Disruptive industries • Disruptive Technologies • Early stage valuations • Equity Valuation • Innovative Companies • investor/entrepreneur behavior • pharma companies • Start-up Valuation • Valuing disruptive start-ups |
ISBN-10 | 3-030-38846-8 / 3030388468 |
ISBN-13 | 978-3-030-38846-1 / 9783030388461 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich